factual

Biotech capital structure yields low success rates

Guo describes traditional biotech as a structure where great firms find principal investigators, own about 40 percent of the company, and assemble candidates that mostly fail, producing a very different distribution of outcomes than a software-like model.

factualpending

Speaker

Sarah Guo

Evidence Quote

“they own 40% of the company and they're kind of assembling these things, turning them into candidates, but most of it doesn't work.”

Source

Sarah Guo - Funding the Frontier - [Invest Like the Best, EP.489]— Invest Like the Best
Created: 11/17/2026, 6:50:18 AM

Your notes

Loading notes...